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ABSTRACT
Background and Aim: Increased xanthine oxidase (XO) activity may contribute to heart failure pathophysiology. 
This study evaluated whether a XO inhibitor, allopurinol produces clinical and functional beneﬁ  ts in patients with 
New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal 
medical therapy as estimated by global left myocardial function. Patients and Methods: Fifty-nine patients with 
a diagnosis of chronic heart failure due to coronary heart disease or idiopathic dilated cardiomyopathy and 20 
healthy controls who attended the outpatient clinic of cardiology were subjected to full echocardiographic study 
including left ventricular diastolic and systolic function, and the combined index of myocardial performance 
[Tei index: isovolumetric relaxation time (IRT) + isovolumetric contraction time (ICT)/ejection time (ET)]. 
Patients were randomized to allopurinol (300 mg/day) or placebo. Improvement at 36 weeks was assessed using 
a composite end point comprising global left cardiac function as well as heart failure morbidity and mortality.
Results: The percentage of patients characterized as improved, unchanged, or worsened did not differ between 
those receiving allopurinol or placebo. Allopurinol reduced serum uric acid (SUA) by 1.5 mg/dL (P = 0.001). 
In a subgroup analysis, patients with elevated SUA (more than 7mg/ dL) responded favorably to allopurinol 
whereas those with SUA less than 7mg/dL exhibited a trend toward no change. In addition, SUA reduction to 
allopurinol correlated with favorable clinical and functional response. Within the entire allopurinol patient cohort, 
those characterized as either improved or unchanged had signiﬁ  cantly greater reductions in SUA compared with 
patients who did not change (P = 0.0007). In placebo patients, lower baseline SUA, but not change in SUA, 
correlated with improved clinical outcome. Conclusions: Allopurinol did not produce signiﬁ  cant clinical and 
functional improvement in unselected patients with moderate-to-severe heart failure. However, it is suggested 
that it is useful in patients with elevated SUA in a manner according to degree of SUA reduction. SUA may 
serve as a valuable biomarker to target heart failure therapy.
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INTRODUCTION
Most epidemiological studies associate increasing serum 
uric acid (SUA) with increased cardiovascular event rate and 
mortality in those with known or elevated risk of vascular 
disease and among healthy volunteers. These data have been 
thoroughly reviewed in many studies.[1] There is a strong 
evidence supporting a pathophysiological role for the 
xanthine oxidase (XO) pathway in heart failure.[2] From a 
functional standpoint, increased XO activity causes cardiac 
mechanoenergetic uncoupling and vascular dysfunction in 
the failing circulation. Therefore, there is a place to improve 
cardiac function by its inhibition. The prototypical (XO) 
inhibitor, allopurinol, has been the cornerstone of the 
clinical management of gout and conditions associated 
with hyperuricemia for several decades. More recent data 
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indicate that XO also plays an important role in various 
forms of ischemic and other types of tissue and vascular 
injuries, inﬂ  ammatory diseases, and chronic heart failure 
(CHF).[3]
Mellin et al.[3] report that short- and long-term (XO) 
inhibition with allopurinol, initiated in rats with CHF due 
to myocardial infarction, improves cardiac hemodynamics 
and function and reverses left ventricular (LV) remodeling.
Echocardiography has introduced the possibility to evaluate 
not only systolic, but also diastolic function. LV systolic 
dysfunction reduces ejection fraction and ejection time, 
and prolongs isovolumetric contraction time. On the other 
hand, LV diastolic dysfunction increases isovolumetric 
relaxation time (IRT) and modiﬁ  es the timing of diastolic 
ﬁ  lling. A relatively new Doppler index of combined systolic 
and diastolic myocardial performance of the left ventricle, 
deﬁ  ned as the sum of the isovolumetric contraction time 
and IRT divided by ejection time, has been reported.[4,5]
This index is easily obtained, reproducible, has a narrow 
range in normal subjects, does not depend on LV geometry, 
and correlates with invasive obtained measures of systolic 
and diastolic cardiac function.[6] This index has been 
reported to be simple and independent of heart rate and 
blood pressure.
This study not only raises an interesting suggestion 
regarding the role of oxidative stress in heart failure, but 
also offers a new pharmacological tool for a novel class 
of heart failure therapeutics: the XO inhibitors. This is 
by the use of a relatively new sensitive Doppler index of 
combined systolic and diastolic myocardial performance 
of the left ventricle  .
PATIENTS AND METHODS
Fifty-nine patients with a diagnosis of CHF due to coronary 
heart disease or idiopathic dilated cardiomyopathy and 
20 healthy controls who attended the outpatient clinic 
of cardiology were subjected to full echocardiographic 
study including LV diastolic and systolic function, and the 
combined index of myocardial performance (Tei index = 
IRT + ICT/ET).[7] Patients were randomized to allopurinol 
(300 mg/day) or placebo. Improvement at 36 weeks was 
assessed using a composite end point comprising global 
left cardiac function as well as heart failure morbidity and 
mortality.
Doppler echocardiographic parameters
Patients were subjected to M-mode and two-dimensional 
(2D) echocardiography with spectral and color flow 
Doppler analysis using a Hewlett-Packard (model Sonos 
1800; Hewlett Packard, Model DR 53 15 Andover, MA) 
ultrasound machine with a 2.5/3.5-MHz transducer. 
Patients were examined in left lateral decubitus position. In 
this study, the following parameters were considered: left 
ventricular end-diastolic (LVDD) and end-systolic (LVSD) 
left ventricular diameters; end-diastolic (RVDD) and end-
systolic (RVSD) right ventricular diameters, interventricular-
septal wall (SWT) and posterior left ventricular wall (PWT) 
thickness (mm). The systolic function was assessed by the 
ejection fraction of the left ventricle (EF) in percentage 
calculated using the area–length method. Diastolic function 
was evaluated by E/A ratio (E velocity = early maximal 
ventricular ﬁ  lling velocity, A velocity = late diastolic or 
atrial velocity), by analysis of trans-mitral (L) ﬂ  ow for the 
assessment of diastolic function.
Left ventricular mass (LVM) was calculated with the 
application of Devereux’s formula:[8] LVM = 1.04 × 
[(LVEDD + LVEDSEP + LVEDPW) –LVEDD 3] –13.6.
Left ventricular total isovolumic ejection index (Tei 
index)
The IRT was measured with the pulsed wave sample volume 
placed between the mitral inﬂ  ow and the LV outﬂ  ow tract. 
The total isovolumic ejection index (Tei index)[9] was 
obtained as the sum of both contraction and relaxation 
isovolumetric periods, divided by the ejection time. These 
Doppler time intervals were measured from mitral inﬂ  ow 
and LV outﬂ  ow velocity spectral signals. Several Doppler 
measurements were made by an independent observer 
blinded to patient diagnosis. The cut-point value for the 
index was considered 0.43 for the left ventricle.[9] 
CONTROLS
Forty control subjects were studied. They were healthy 
volunteers. The same procedures for the echocardiographic 
examinations were applied.
Statistical analysis
Data are expressed as mean ± SE. The statistical 
signiﬁ  cance of the differences between the groups was 
calculated using Student’s t-test for independent means. 
Two-tailed values of P < 0.05 were considered signiﬁ  cant.
Ethical consideration
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and the value of the work were explained in a simpliﬁ  ed 
manner for them. There was no harm inﬂ  icted on them. 
On the contrary, all had beneﬁ  ts of the follow-up and the 
ﬁ  nal results of the study.
RESULTS 
The percentage of patients characterized as improved, 
unchanged, or worsened did not differ between those 
receiving allopurinol or placebo. Allopurinol reduced 
SUA by 1.5 mg/dL (P = 0.001). In a subgroup analysis, 
patients with elevated SUA (more than 7mg/dL) responded 
favorably to allopurinol whereas those with SUA less than 
7 mg/dL exhibited a trend toward no change. Within the 
entire allopurinol patient cohort, those characterized as 
either improved or unchanged had signiﬁ  cantly greater 
reductions in SUA compared with patients who did not 
change. In placebo patients, lower baseline SUA, but not 
change in SUA, correlated with improved clinical outcome.
Regarding clinical improvement, there existed non-
signiﬁ  cant changes regarding symptoms of heart failure 
with no signiﬁ  cant change in the grade of dyspnea.
Functional echocardiography ﬁ  ndings in controls and heart 
failure patients due to coronary heart disease before and 
after 36 weeks after receiving allopurinol (300 mg/day) 
are shown in Table 1. On the other hand, Table 2 shows 
functional echocardiography ﬁ  ndings in controls and heart 
failure patients due to idiopathic dilated cardiomyopathy 
before and after 36 weeks of receiving allopurinol (300 
mg/day).
DISCUSSION
Chronic heart failure is characterized by a progressive LV 
remodeling[10,11] and despite the introduction of newer 
drugs, it has a poor prognosis.[12] Although the involvement 
of systemic and cardiac hemodynamics and neurohumoral 
factors in the progression of CHF are extensively studied 
and are recognized as therapeutic targets.[13-15]
Oxygen free radical generation has been proposed to be 
an important mechanism of cellular injury in ischemic and 
reperfused tissues. Studies in a variety of tissues, including 
heart, lung, kidney, and brain, have demonstrated that 
intravascular administration of antioxidant enzymes or free 
radical-scavenging drugs can prevent reperfusion damage 
and improve postischemic function.[16]
Although several mechanisms have been demonstrated to 
be involved in the generation of oxygen free radicals, XO 
has been proposed to be a central mechanism in a variety 
of postischemic cells and tissues.[17] Although there has 
been controversy regarding whether this mechanism occurs 
in human cells and tissues, recent studies have shown that 
the enzyme is present in human endothelial cells and is 
responsible for free radical generation in reoxygenated 
human endothelial cells.[17] 
In patients with idiopathic dilated cardiomyopathy, 
Table 2: Functional echocardiography ﬁ  ndings in controls and heart failure patients due to idiopathic dilated 
cardiomyopathy before and after 36 weeks of receiving allopurinol (300 mg/day)
Parameters  Groups
Control, N = 20 Heart failure due to idiopathic dilated 
cardiomyopathy (n = 25)
Before After Before After
Mean ±SD Mean ±SD Mean ±SD Mean ±SD
EF % 62.7 5.5 62.9 5.3 36.5 3.9 39.5 4.1
Tei index 0.41 3.8 0.41 3.9 0.61 4.8 0.60 3.3
E/A 1.3 0.3 1.2 0.4 0.7 0.55 0.8 0.6
*Signiﬁ  cance at <0.05.
Table 1: Functional echocardiography ﬁ  ndings in controls and heart failure patients due to coronary heart disease 
before and after 36 weeks after receiving allopurinol (300 mg/day)
Parameters  Groups
Control (n = 20) Heart failure due to coronary heart disease (n = 34)
Before After Before After
Mean ±SD Mean ±SD Mean ±SD Mean ±SD
EF % 62.7 5.5 62.9 5.3 46.5 3.9 47.5 4.3
Tei index 0.41  3.8 0.41 3.9 0.49  5.4 0.47 3.8
E/A 1.3  0.3 1.2 0.4 0.9 0.3 0.85 0.7
*Signiﬁ  cance at <0.05.194 Journal of Cardiovascular Disease Research Vol. 1 / No 4
Nasr and Maurice: Allopurinol and global left myocardial function 
intracoronary administration of allopurinol resulted in an 
acute, signiﬁ  cant improvement in myocardial efﬁ  ciency 
by diminishing oxygen consumption in the presence 
of standard supportive therapy.[18] CHF also results in 
an impairment of peripheral vascular reactivity. Acute 
intravenous infusion of allopurinol or chronic treatment 
with the drug for 1 month improved endothelial function in 
patients, as evaluated by the measurement of acetylcholine-
induced ﬂ  ow responses.[19] 
Some studies have shown that short-term administration of 
allopurinol improves myocardial efﬁ  ciency in patients with 
idiopathic dilated cardiomyopathy by decreasing the oxygen 
cost of LV contraction.[18] However, this was not evident in 
this study as allopurinol did not produce signiﬁ  cant clinical 
and functional improvement in unselected patients with 
moderate-to-severe heart failure. However, it is suggested 
that it is useful in patients with elevated SUA in a manner 
according to degree of SUA reduction. This focuses upon 
the importance of SUA as a valuable biomarker to target 
heart failure therapy.
In agreement with this, a recent study who demonstrated 
that oxypurinol did not improve a clinical composite score 
in patients with systolic, symptomatic heart failure, and 
could potentially cause harm to some patients. Subgroup 
analysis supports the concept that patients with these 
clinical characteristics and a high SUA may beneﬁ  t from 
XO inhibition. Moreover, the degree of SUA reduction 
correlated with clinical outcome, such that patients who 
worsened despite oxypurinol therapy had relatively less 
reduction in uric acid. Measurements of uric acid may aid 
in individualizing therapy with XO inhibitors.[20]
There are several reasons why oxypurinol may not have led 
to clinical beneﬁ  ts in the broad population of symptomatic, 
treated patients. First, it is possible that sources of oxidative 
stress are already inhibited by other medications such as 
inhibitors of the rennin–angiotensin–aldosterone pathway 
or carvedilol. In this regard, angiotensin II can activate XO 
directly[21] and indirectly via NADPH oxidase.[22]
 However, more larger studies are needed as XO inhibitor 
therapy in myocardial infarction and CHF appear appealing 
possibility for various reasons. First, there is evidence 
that increased levels of uric acid strongly correlate with 
mortality rates in congestive heart failure,[23] and XO 
inhibitors exert certain beneﬁ  cial effects both in animals 
and humans with heart failure. Second, allopurinol and 
its active metabolite oxypurinol are well known and 
relatively safe drugs that have been used for decades to 
treat gout. Third, the mechanism of action is unique and 
thus would be expected to potentiate the beneﬁ  cial effects 
of conventional therapeutic agents (e.g., β-blockers and 
angiotensin-converting enzyme inhibitors).[24]
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